This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, X.-Y. Articles by Dong, J.-T. Search for Related Content PubMed PubMed Citation Articles by Dong, X.-Y. Articles by Dong, J.-T.

FOXO1A Is a Candidate for the 13q14 Tumor Suppressor Gene Inhibiting Androgen Receptor Signaling in Prostate Cancer

¹ Department of Hematology and Oncology, Winship Cancer Institute, and ² Department of Urology, Emory University School of Medicine, Atlanta, Georgia; ³ Department of Urology, University of Washington, Seattle, Washington; and ⁴ Nankai University College of Life Sciences, Tianjin, China

Requests for reprints: Jin-Tang Dong, Winship Cancer Institute, Emory University, Room C4080, 1365-C Clifton Road, Atlanta, GA 30322. Phone: 404-712-2568; Fax: 404-712-2571; E-mail: jdong2{at}emory.edu.

Chromosomal deletion is frequent at the region between BRCA2 and RB1 in the q14 band of chromosome 13 (13q14) in human cancers, including prostate cancer, suggesting the presence of a tumor suppressor gene. However, no reasonable candidate has been identified thus far. In this study, we did genetic and functional analyses to identify and evaluate the 13q14 tumor suppressor gene. Hemizygous and homozygous deletions in cell lines/xenografts of prostate cancer mapped the deletion locus to 919 kb, which harbors only one known gene, the FOXO1A transcription factor. Deletion at FOXO1A was detected in 31% to 34% in 6 cell lines, 27 xenografts, and 72 clinical specimens of prostate cancer, and was significantly more frequent than deletions at surrounding loci. In addition, FOXO1A was transcriptionally down-regulated in some prostate cancers. Functionally, ectopic expression of FOXO1A inhibited, and its knockdown promoted, cell proliferation or survival. Furthermore, FOXO1A inhibited androgen- and androgen receptor–mediated gene regulation and cell proliferation. Consistent with the understanding of FOXO1A biology, our findings suggest that FOXO1A is the 13q14 tumor suppressor gene, at least in prostate cancer. As a well-established negative effector in the phosphatidylinositol 3-kinase/AKT signaling pathway, FOXO1A inactivation in cancer would impair the therapeutic effect of phosphatidylinositol 3-kinase/AKT inhibitors in cancer treatment. (Cancer Res 2006; 66(14): 6998-7006)

This article has been cited by other articles:

				L. Gan, S. Chen, Y. Wang, A. Watahiki, L. Bohrer, Z. Sun, Y. Wang, and H. Huang Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer Cancer Res., November 1, 2009; 69(21): 8386 - 8394. [Abstract] [Full Text] [PDF]

				I. K. Guttilla and B. A. White Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells J. Biol. Chem., August 28, 2009; 284(35): 23204 - 23216. [Abstract] [Full Text] [PDF]

				W. Fu, Q. Ma, L. Chen, P. Li, M. Zhang, S. Ramamoorthy, Z. Nawaz, T. Shimojima, H. Wang, Y. Yang, et al. MDM2 Acts Downstream of p53 as an E3 Ligase to Promote FOXO Ubiquitination and Degradation J. Biol. Chem., May 22, 2009; 284(21): 13987 - 14000. [Abstract] [Full Text] [PDF]

				Q. Ma, W. Fu, P. Li, S. V. Nicosia, G. Jenster, X. Zhang, and W. Bai FoxO1 Mediates PTEN Suppression of Androgen Receptor N- and C-Terminal Interactions and Coactivator Recruitment Mol. Endocrinol., February 1, 2009; 23(2): 213 - 225. [Abstract] [Full Text] [PDF]

				J.-Y. Yang and M.-C. Hung A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer Clin. Cancer Res., February 1, 2009; 15(3): 752 - 757. [Abstract] [Full Text] [PDF]

				P. Liu, S. Li, L. Gan, T. P. Kao, and H. Huang A Transcription-Independent Function of FOXO1 in Inhibition of Androgen-Independent Activation of the Androgen Receptor in Prostate Cancer Cells Cancer Res., December 15, 2008; 68(24): 10290 - 10299. [Abstract] [Full Text] [PDF]

				C. Weidinger, K. Krause, A. Klagge, S. Karger, and D. Fuhrer Forkhead box-O transcription factor: critical conductors of cancer's fate Endocr. Relat. Cancer, December 1, 2008; 15(4): 917 - 929. [Abstract] [Full Text] [PDF]

				X.-Y. Dong, C. Rodriguez, P. Guo, X. Sun, J. T. Talbot, W. Zhou, J. Petros, Q. Li, R. L. Vessella, A. S. Kibel, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer Hum. Mol. Genet., April 1, 2008; 17(7): 1031 - 1042. [Abstract] [Full Text] [PDF]

				H. V. Heemers and D. J. Tindall Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex Endocr. Rev., December 1, 2007; 28(7): 778 - 808. [Abstract] [Full Text] [PDF]

				E. C. Bolton, A. Y. So, C. Chaivorapol, C. M. Haqq, H. Li, and K. R. Yamamoto Cell- and gene-specific regulation of primary target genes by the androgen receptor Genes & Dev., August 15, 2007; 21(16): 2005 - 2017. [Abstract] [Full Text] [PDF]